The National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) as an additional treatment option for moderate to severe Atopic Dermatitis in England. Lebrikizumab is indicated for adults and adolescents (12 years and older) with moderate-to-severe Atopic Dermatitis who are candidates for systemic therapy.
The recommendation is significant as it provides eligible patients with another treatment option for this common skin condition. Moderate to severe Atopic Dermatitis affects approximately 7.7% of adults and 18% of children in the United Kingdom. It can have significant physical and psychosocial impacts on patients and their families, including itching, bleeding skin, and social stigma.
Ebglyss has demonstrated efficacy in clinical trials, with a favorable safety profile and 4-weekly maintenance dosing. It is a targeted biological therapy that addresses the underlying inflammation in Atopic Dermatitis, relieving symptoms and improving quality of life.
Experts in the field have welcomed the NICE recommendation. Andrew Proctor, Chief Executive of the National Eczema Society, emphasizes the importance of having a range of treatment options for Atopic Dermatitis. Jorgen Damsbo, General Manager at Almirall, UK, highlights the company’s commitment to transforming patients’ lives through innovative treatments.
Prof Tony Bewley, Consultant Dermatologist, emphasizes the significant psychosocial burden of Atopic Dermatitis and the potential benefits of targeted biological therapies like Ebglyss. He notes the encouraging advancements in drug development for this chronic condition and the importance of providing patients with effective and accessible treatment options.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.